Trust your gut: The Tipline for 20 November 2019

While Jonathan Baker, author of The Antitrust Paradigm, is calling on antitrust authorities to focus enforcement on harms to future products and innovation, one technology enforcer at the Federal Trade Commission is playing a little defence. Patricia Galvan pointed to the FTC’s work in the pharmaceuticals sector as an example of how the agency “consistently brings cases” when an acquisition of a competitor with a product in development is viewed as problematic. And in New York, the Department of Justice and counsel to former currency trader Akshay Aiyer jammed a 12-day trial into a single day of closing arguments.

Unlock unlimited access to all Global Competition Review content